Assyro AI

FDA Orange Book · active-ingredient family

Nitrofurantoin, macrocrystalline

Nitrofurantoin, macrocrystalline is approved as 1 brand and 14 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:MACRODANTIN · NDA 016620

1

Brand (NDA)

14

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule

ProductApplicantApplicationTEApproved
MACRODANTINRLD×3ALMATICANDA 016620ABApproved Prior to Jan 1, 1982

Generic (ANDA) products (14)

ProductApplicantApplicationTEApproved
NITROFURANTOIN×2AUROBINDO PHARMA USAANDA 077025ABOct 02, 2024
NITROFURANTOIN×3MANKIND PHARMAANDA 217272ABMar 21, 2023
NITROFURANTOIN×3ALEMBICANDA 211935ABJun 25, 2021
NITROFURANTOIN×2NOVEL LABS INCANDA 203233ABJul 09, 2018
NITROFURANTOIN×2ZYDUS PHARMSANDA 205005ABDec 12, 2017
NITROFURANTOIN×3SUN PHARM INDUSTRIESANDA 201722Feb 16, 2016
NITROFURANTOIN×3ACTAVIS LABS FL INCANDA 091095Jun 18, 2015
NITROFURANTOIN×2AUROBINDO PHARMA USAANDA 074967ABJul 09, 1997
NITROFURANTOIN×3POM PHARMAANDA 074336Jan 25, 1995
NITROFURANTOINIMPAX LABS INCANDA 073671ABJan 28, 1993
NITROFURANTOINIMPAX LABS INCANDA 073652ABJan 28, 1993
NITROFURANTOIN×3WATSON LABSANDA 073696Dec 31, 1992
NITROFURANTOIN MACROCRYSTALLINEWATSON LABSANDA 070248Jun 24, 1988
NITROFURANTOIN MACROCRYSTALLINEWATSON LABSANDA 070249Jun 24, 1988

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Nitrofurantoin, macrocrystalline — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.